2.1
Fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) is indicated for 'the treatment of vision impairment associated with chronic diabetic macular oedema, (DMO) considered insufficiently responsive to available therapies'.
2 Information about fluocinolone acetonide intravitreal implant
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for fluocinolone acetonide intravitreal implant.
Price
2.3
2.4
The company has a commercial arrangement. This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.